CTNI-49. PHASE I STUDY OF MGMT-P140K TRANSFECTED HEMATOPOETIC PROGENITOR CELLS COMBINED WITH TMZ/O6BG DOSE ESCALATION FOR NEWLY DIAGNOSED, UNMETHYLATED GLIOBLASTOMA: TOLERANCE AND EVIDENCE OF SURVIVAL BENEFIT

CTNI-49. PHASE I STUDY OF MGMT-P140K TRANSFECTED HEMATOPOETIC PROGENITOR CELLS COMBINED WITH TMZ/O6BG DOSE ESCALATION FOR NEWLY DIAGNOSED, UNMETHYLATED GLIOBLASTOMA: TOLERANCE AND EVIDENCE OF SURVIVAL BENEFIT

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2020-11, Vol.22 (Supplement_2), p.ii53-ii53
Hauptverfasser: Sloan, Andrew E, Fung, Hua, Reese, Jane, Rgers, Lisa, Murphy, Christopher, Lazarus, Hillard, Dropulic, Boro, Gerson, Stanton
Format: Artikel
Sprache:eng
Schlagworte:
Clinical Trials: Non-Immunologic
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page ii53
container_issue Supplement_2
container_start_page ii53
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 22
creator Sloan, Andrew E
Fung, Hua
Reese, Jane
Rgers, Lisa
Murphy, Christopher
Lazarus, Hillard
Dropulic, Boro
Gerson, Stanton
description
doi_str_mv 10.1093/neuonc/noaa215.215
format Article
fullrecord <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7651599</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_7651599</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1425-c161f95d63a4ee350cbce276010b9420f25238320ab7b1f2d7ebc75f90cdcf053</originalsourceid><addsrcrecordid>eNpVUdFumzAURdMmrev6A3u6HzAS22AIe5jkgAGrxo6Ckyp7QUBgy9RCBeuk_mU_qe5STerDta91zzn3yMdxvmC0wCjylkP3MA7tchjrmmC6sPXOucCUeC5dBcH7fz1xVxSHH51P8_wbIQsJ8IXzFBslXD9awCZnJQcBpdklB9ApFFlh3A320TWYLVNlymPDE8h5wYzeaG5EDJutzrgSRm8h5lKWEOtiLZSF3QiTgyl-LHWwziDRVpuXMZPMCK0gtQTFb-QBEsEyZafJV9ipgpv8YCGWn0mh15KVRhfsGxgtufUQc2AqAb4XCX95WJflbrsXeyZhzRVPhfnsfOjr27m7er0vnV3KTZy7UmfC7ndb7BNqzwD3ET0GXu13nUdR27QdCQOEURP5BPXEft7KI6huwgb35Bh2TRvSPkLtse0R9S6d72fd-4fmrju23fBnqm-r--l0V0-P1VifqreT4fSr-jn-rcKAYhpFVoCcBdppnOep6_9zMapeQq3OoVavoVa2vGdgl4p3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>CTNI-49. PHASE I STUDY OF MGMT-P140K TRANSFECTED HEMATOPOETIC PROGENITOR CELLS COMBINED WITH TMZ/O6BG DOSE ESCALATION FOR NEWLY DIAGNOSED, UNMETHYLATED GLIOBLASTOMA: TOLERANCE AND EVIDENCE OF SURVIVAL BENEFIT</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sloan, Andrew E ; Fung, Hua ; Reese, Jane ; Rgers, Lisa ; Murphy, Christopher ; Lazarus, Hillard ; Dropulic, Boro ; Gerson, Stanton</creator><creatorcontrib>Sloan, Andrew E ; Fung, Hua ; Reese, Jane ; Rgers, Lisa ; Murphy, Christopher ; Lazarus, Hillard ; Dropulic, Boro ; Gerson, Stanton</creatorcontrib><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noaa215.215</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Clinical Trials: Non-Immunologic</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii53-ii53</ispartof><rights>The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651599/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651599/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Sloan, Andrew E</creatorcontrib><creatorcontrib>Fung, Hua</creatorcontrib><creatorcontrib>Reese, Jane</creatorcontrib><creatorcontrib>Rgers, Lisa</creatorcontrib><creatorcontrib>Murphy, Christopher</creatorcontrib><creatorcontrib>Lazarus, Hillard</creatorcontrib><creatorcontrib>Dropulic, Boro</creatorcontrib><creatorcontrib>Gerson, Stanton</creatorcontrib><title>CTNI-49. PHASE I STUDY OF MGMT-P140K TRANSFECTED HEMATOPOETIC PROGENITOR CELLS COMBINED WITH TMZ/O6BG DOSE ESCALATION FOR NEWLY DIAGNOSED, UNMETHYLATED GLIOBLASTOMA: TOLERANCE AND EVIDENCE OF SURVIVAL BENEFIT</title><title>Neuro-oncology (Charlottesville, Va.)</title><subject>Clinical Trials: Non-Immunologic</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVUdFumzAURdMmrev6A3u6HzAS22AIe5jkgAGrxo6Ckyp7QUBgy9RCBeuk_mU_qe5STerDta91zzn3yMdxvmC0wCjylkP3MA7tchjrmmC6sPXOucCUeC5dBcH7fz1xVxSHH51P8_wbIQsJ8IXzFBslXD9awCZnJQcBpdklB9ApFFlh3A320TWYLVNlymPDE8h5wYzeaG5EDJutzrgSRm8h5lKWEOtiLZSF3QiTgyl-LHWwziDRVpuXMZPMCK0gtQTFb-QBEsEyZafJV9ipgpv8YCGWn0mh15KVRhfsGxgtufUQc2AqAb4XCX95WJflbrsXeyZhzRVPhfnsfOjr27m7er0vnV3KTZy7UmfC7ndb7BNqzwD3ET0GXu13nUdR27QdCQOEURP5BPXEft7KI6huwgb35Bh2TRvSPkLtse0R9S6d72fd-4fmrju23fBnqm-r--l0V0-P1VifqreT4fSr-jn-rcKAYhpFVoCcBdppnOep6_9zMapeQq3OoVavoVa2vGdgl4p3</recordid><startdate>20201109</startdate><enddate>20201109</enddate><creator>Sloan, Andrew E</creator><creator>Fung, Hua</creator><creator>Reese, Jane</creator><creator>Rgers, Lisa</creator><creator>Murphy, Christopher</creator><creator>Lazarus, Hillard</creator><creator>Dropulic, Boro</creator><creator>Gerson, Stanton</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20201109</creationdate><title>CTNI-49. PHASE I STUDY OF MGMT-P140K TRANSFECTED HEMATOPOETIC PROGENITOR CELLS COMBINED WITH TMZ/O6BG DOSE ESCALATION FOR NEWLY DIAGNOSED, UNMETHYLATED GLIOBLASTOMA: TOLERANCE AND EVIDENCE OF SURVIVAL BENEFIT</title><author>Sloan, Andrew E ; Fung, Hua ; Reese, Jane ; Rgers, Lisa ; Murphy, Christopher ; Lazarus, Hillard ; Dropulic, Boro ; Gerson, Stanton</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1425-c161f95d63a4ee350cbce276010b9420f25238320ab7b1f2d7ebc75f90cdcf053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Clinical Trials: Non-Immunologic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sloan, Andrew E</creatorcontrib><creatorcontrib>Fung, Hua</creatorcontrib><creatorcontrib>Reese, Jane</creatorcontrib><creatorcontrib>Rgers, Lisa</creatorcontrib><creatorcontrib>Murphy, Christopher</creatorcontrib><creatorcontrib>Lazarus, Hillard</creatorcontrib><creatorcontrib>Dropulic, Boro</creatorcontrib><creatorcontrib>Gerson, Stanton</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sloan, Andrew E</au><au>Fung, Hua</au><au>Reese, Jane</au><au>Rgers, Lisa</au><au>Murphy, Christopher</au><au>Lazarus, Hillard</au><au>Dropulic, Boro</au><au>Gerson, Stanton</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CTNI-49. PHASE I STUDY OF MGMT-P140K TRANSFECTED HEMATOPOETIC PROGENITOR CELLS COMBINED WITH TMZ/O6BG DOSE ESCALATION FOR NEWLY DIAGNOSED, UNMETHYLATED GLIOBLASTOMA: TOLERANCE AND EVIDENCE OF SURVIVAL BENEFIT</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2020-11-09</date><risdate>2020</risdate><volume>22</volume><issue>Supplement_2</issue><spage>ii53</spage><epage>ii53</epage><pages>ii53-ii53</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noaa215.215</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii53-ii53
issn 1522-8517
1523-5866
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7651599
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Clinical Trials: Non-Immunologic
title CTNI-49. PHASE I STUDY OF MGMT-P140K TRANSFECTED HEMATOPOETIC PROGENITOR CELLS COMBINED WITH TMZ/O6BG DOSE ESCALATION FOR NEWLY DIAGNOSED, UNMETHYLATED GLIOBLASTOMA: TOLERANCE AND EVIDENCE OF SURVIVAL BENEFIT
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T21%3A35%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CTNI-49.%20PHASE%20I%20STUDY%20OF%20MGMT-P140K%20TRANSFECTED%20HEMATOPOETIC%20PROGENITOR%20CELLS%20COMBINED%20WITH%20TMZ/O6BG%20DOSE%20ESCALATION%20FOR%20NEWLY%20DIAGNOSED,%20UNMETHYLATED%20GLIOBLASTOMA:%20TOLERANCE%20AND%20EVIDENCE%20OF%20SURVIVAL%20BENEFIT&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Sloan,%20Andrew%20E&rft.date=2020-11-09&rft.volume=22&rft.issue=Supplement_2&rft.spage=ii53&rft.epage=ii53&rft.pages=ii53-ii53&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noaa215.215&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_7651599%3C/pubmedcentral_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true